Bedrijfsoverzicht
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on the development and commercialization of investigational therapies designed to treat chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, as well as those with refractory chronic cough. Operating within the broader Healthcare sector and specifically the Biotechnology industry, the company functions as a specialized entity dedicated to advancing novel treatments for rare and serious respiratory conditions. The organization currently employs 34 individuals and maintains a market capitalization of $1.69 billion, a valuation that reflects investor sentiment toward its potential pipeline despite the absence of reported annual revenue figures in the available data. The specific market cap figure of $1.69B combined with the lack of reported revenue indicates that the company's value is primarily derived from its clinical-stage assets and future growth potential rather than current operational profitability, characteristic of early-stage biotechnology firms.
Financiële gezondheid
Trevi Therapeutics reports a Net Income (TTM) of $-42,759,000 and an EBITDA of $-49,184,000, while the Revenue (TTM) is listed as N/A, a situation typical for clinical-stage companies where costs for research, development, and clinical trials significantly outweigh current sales. The substantial gap between the reported net income and EBITDA, alongside the zero gross margin, suggests a cost structure heavily weighted toward operational expenses and clinical trial costs before reaching a stage where revenue generation offsets these expenditures. The company's Free Cash Flow stands at $-27,859,000, indicating a continuous burn rate that limits immediate financial flexibility and necessitates reliance on external capital sources or existing cash reserves to fund ongoing operations. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability from its sales or operations, a standard condition for entities still validating their technology in clinical trials. Regarding liquidity, the company holds $188.26M in cash against a minimal debt load of $753,000, resulting in a Debt to Equity ratio of 0.41, which demonstrates a conservative balance sheet structure with very limited leverage. The Current Ratio is an exceptionally high 19.66, indicating that the company possesses ample short-term assets relative to its short-term liabilities, thereby ensuring robust liquidity positioning despite the negative cash flow. Furthermore, the Return on Equity is -30.2% and the Return on Assets is -20.3%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, a consequence of heavy investment phases rather than operational inefficiency.
Waarderingsbeoordeling
The Trailing P/E Ratio (TTM) is N/A due to negative earnings, whereas the Forward P/E is -23.35; the negative forward valuation metric implies that analysts or the market is pricing in a trajectory where earnings are expected to improve from their current negative baseline, though the exact path to profitability remains to be realized. The Price to Book ratio is 9.24, a figure that indicates a significant market premium over the company's book value, suggesting that investors are valuing the intangible assets and potential of the clinical pipeline far above the tangible net assets currently recorded on the balance sheet. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -30.62, provide context for investors by highlighting that traditional multiple-based comparisons are not applicable until positive revenue and earnings are generated. The stock has experienced significant volatility over the past year, trading between a 52-week high of $14.39 and a 52-week low of $5.38, placing the current trading environment within a wide range that reflects the high-risk nature of the biotechnology sector. The Beta value is exactly 1.00, which indicates that the price volatility of TRVI moves in tandem with the broader market, lacking the typical high-beta volatility often seen in small-cap biotech stocks during periods of market stress or rally.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning that historical growth rates cannot be calculated from the current data points, preventing a direct comparison of earnings acceleration relative to revenue expansion. Since the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which signifies that the company reinvests all available resources back into the business rather than distributing income to shareholders. The absence of a dividend payout ratio confirms that the company's strategy is focused on funding research and development to achieve clinical milestones rather than providing immediate income returns to investors. In summary, the overall growth and income profile for Trevi Therapeutics is currently defined by a reinvestment strategy aimed at transitioning the company from a clinical-stage entity to a profitable commercial operation, with no current income generation or historical growth metrics available for analysis.